LLY vs SNDX

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Syndax shows strong commercial momentum with Revuforj and Niktimvo sales annualizing near $200 million each, validating its market opportunity in oncology with 224% YoY revenue growth. The significant narrowing of net loss in Q1 2026, beating EPS estimates, addresses prior profitability concerns and indicates a better path towards sustainable operations, despite a minor revenue miss. The company m...